LGF
NKTR icon

LGT Group Foundation’s Nektar Therapeutics NKTR Stock Holding History

LGT Group Foundation’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-750
Closed -$7.65K – 300
2025
Q1 		$7.65K Hold
750
– – ﹤0.01% 288
2024
Q4 		$10.5K Hold
750
– – ﹤0.01% 272
2024
Q3 		$15K Hold
750
– – ﹤0.01% 283
2024
Q2 		$13.9K Buy
+750
New +$15.8K ﹤0.01% 265

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LGT Group Foundation's NKTR Position: Q2 2025 in Review

LGT Group Foundation sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 750 shares — an estimated $7.65K sold.

LGT Group Foundation first reported a position in NKTR in Q2 2024 and held it in 4 quarters. The position peaked at $15K in Q3 2024. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • LGT Group Foundation reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • LGT Group Foundation sold 750 Nektar Therapeutics shares in Q2 2025, an estimated $7.65K.
  • LGT Group Foundation first reported a position in Nektar Therapeutics in Q2 2024 and held it in 4 quarters.
  • LGT Group Foundation's Nektar Therapeutics position peaked at $15K in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on LGT Group Foundation's 13F filing for Q2 2025, filed 22 Jul 2025.